$LDSN
Luduson G Inc.

2023 Q2 Form 10-Q Financial Statement

#000168316823003483 Filed on May 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $0.00 $0.00 $19.17K
YoY Change -100.0% -100.0% -74.23%
Cost Of Revenue $0.00 $0.00 $1.920K
YoY Change -98.5%
Gross Profit $0.00 $0.00 $17.25K
YoY Change -100.0% -100.0% -132.27%
Gross Profit Margin 89.98%
Selling, General & Admin $3.330K $148.0K
YoY Change -96.41% -97.06%
% of Gross Profit 857.91%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $38.17K
YoY Change -100.0% -100.0% -0.62%
% of Gross Profit 221.28%
Operating Expenses $3.330K $0.00 $148.0K
YoY Change -96.41% -100.0% -97.06%
Operating Profit -$3.330K $0.00 -$130.7K
YoY Change -95.83% -100.0% -97.43%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $45.26K
YoY Change -100.0%
Pretax Income -$3.325K $0.00 -$85.48K
YoY Change -92.86% -100.0% -98.32%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.325K $0.00 -$85.48K
YoY Change -92.86% -100.0% -98.32%
Net Earnings / Revenue -445.91%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 28.21M shares 28.21M shares 28.21M shares
Diluted Shares Outstanding 28.21M shares 28.21M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.21K
YoY Change 12731.03%
Cash & Equivalents $0.00 $0.00 $0.00
Short-Term Investments
Other Short-Term Assets $1.435M
YoY Change -6.08%
Inventory
Prepaid Expenses
Receivables $19.21K
Other Receivables $0.00
Total Short-Term Assets $0.00 $2.821K $2.821K
YoY Change -100.0% -99.82% -99.83%
LONG-TERM ASSETS
Property, Plant & Equipment $109.4K
YoY Change -58.36%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $0.00 $2.821K $2.821K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $0.00 $2.821K $2.821K
YoY Change -100.0% -99.85% -99.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $137.5K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $81.50K $81.00K $81.00K
YoY Change -91.51% -91.42% -91.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $81.50K $81.00K $81.00K
Total Long-Term Liabilities $0.00
Total Liabilities $81.50K $81.00K $81.00K
YoY Change -91.51% -91.42% -91.46%
SHAREHOLDERS EQUITY
Retained Earnings -$1.117M -$1.113M -$1.113M
YoY Change 496.66% 2077.28%
Common Stock $2.821K $2.821K $2.821K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$81.50K -$78.18K -$78.18K
YoY Change
Total Liabilities & Shareholders Equity $0.00 $2.821K $2.821K
YoY Change -100.0% -99.85% -99.85%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$3.325K $0.00 -$85.48K
YoY Change -92.86% -100.0% -98.32%
Depreciation, Depletion And Amortization $0.00 $0.00 $38.17K
YoY Change -100.0% -100.0% -0.62%
Cash From Operating Activities -$2.820K $0.00 $38.72K
YoY Change -133.33% -100.0% -281.61%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.820K
YoY Change
Cash From Investing Activities $2.820K $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 -8.790K
YoY Change -100.0% -79.48%
NET CHANGE
Cash From Operating Activities -2.820K $0.00 38.72K
Cash From Investing Activities 2.820K $0.00 0.000
Cash From Financing Activities $0.00 -8.790K
Net Change In Cash 0.000 $0.00 29.93K
YoY Change -100.0% -100.0% -146.65%
FREE CASH FLOW
Cash From Operating Activities -$2.820K $0.00 $38.72K
Capital Expenditures $0.00 $0.00
Free Cash Flow $0.00 $38.72K
YoY Change -281.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Trading Symbol
TradingSymbol
LDSN
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28210000 shares
CY2023Q1 LDSN Investment In Unlisted Shares
InvestmentInUnlistedShares
2821 usd
CY2022Q4 LDSN Investment In Unlisted Shares
InvestmentInUnlistedShares
2821 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
2821 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2821 usd
CY2023Q1 us-gaap Assets
Assets
2821 usd
CY2022Q4 us-gaap Assets
Assets
2821 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001737193
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38457
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Luduson G Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3184409
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
17/F
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
80 Gloucester Road
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Wanchai
CY2023Q1 dei Entity Address Country
EntityAddressCountry
HK
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
00000
CY2023Q1 dei City Area Code
CityAreaCode
+852
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
2818 7199
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value US$0.0001
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
81000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
81000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
81000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
81000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
81000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
81000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28210000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28210000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28210000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28210000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2821 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2821 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1032179 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1032179 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1113179 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1113179 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-78179 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-78179 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2821 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2821 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
CY2022Q1 us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
-0 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
-0 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
-0 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
-0 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
0 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
0 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
0 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28210000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28210000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28210000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28210000 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
0 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
0 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
0 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-35179 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
0 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-35179 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-78179 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
0 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-78179 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zUUjgD4gH5de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.4pt; text-align: justify; text-indent: -30.1pt"><span style="font-family: Wingdings">l</span>   <span id="xdx_86B_zHZFINVcKNP7">Use of estimates and assumptions</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these condensed financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheet and revenues and expenses during the periods reported. Actual results may differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p>
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28210000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28210000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28210000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28210000 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2500000 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2500000 shares
CY2022Q4 LDSN Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
2500000 shares
CY2023Q1 LDSN Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
2500000 shares

Files In Submission

Name View Source Status
0001683168-23-003483-index-headers.html Edgar Link pending
0001683168-23-003483-index.html Edgar Link pending
0001683168-23-003483.txt Edgar Link pending
0001683168-23-003483-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
ldsn-20230331.xsd Edgar Link pending
luduson_ex3101.htm Edgar Link pending
luduson_ex3102.htm Edgar Link pending
luduson_ex3201.htm Edgar Link pending
luduson_ex3202.htm Edgar Link pending
luduson_i10q-033123.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ldsn-20230331_cal.xml Edgar Link unprocessable
ldsn-20230331_def.xml Edgar Link unprocessable
ldsn-20230331_lab.xml Edgar Link unprocessable
ldsn-20230331_pre.xml Edgar Link unprocessable
luduson_i10q-033123_htm.xml Edgar Link completed